FIG. 2.

(A) Tenofovir (TFV) in plasma versus DBSs and (B) emtricitabine (FTC) in plasma versus DBSs. DBSs and plasma were obtained from the same blood draw from three participants over two intensive pharmacokinetic studies of TDF-FTC. One pharmacokinetics visit was after the first dose and the other was after the last dose before drug discontinuation. The linear regression for TFV in plasma versus DBSs was 1.4x, r²=0.96 and that for FTC in plasma versus DBSs was 0.8x, r²=0.99. The regression did not account for repeated measures.